Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SABRATEK CORP (SBTK) -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (297)	7/7/1999 1:43:00 PM
From: mod	Read Replies (1) \| Respond to of 487

CFSB reiterates Buy rating, price target $30: Sabratek CREDIT SUISSE FIRST BOSTON CORPORATION Equity Research Americas United States/Medical Supplies and Devices July 6, 1999 Sabratek BUY SBTK Sabratek Acquires Critical Telemedicine Component · As expected, Sabratek completed the outright purchase of MOON Communications after two years of an exclusive licensing arrangement. Total consideration for the license and purchase approximates $19 million in cash and stock. · MOON is the central operating system of the telemedicine business, facilitating connectivity between patients, physicians, payors, clinical providers, and other health care constituents. This acquisition is an important milestone to establishing a leading telemedicine business. · Sabratek's long standing relationship with MOON should facilitate a smooth integration with few surprises. · The company also announced plans to launch an internet portal (www.OneMedPlace.com) to the MOON/telemedicine business. · We reiterate our Buy rating on Sabratek common. We believe substantial value will be unlocked as visibility for the telemedicine business increases. Potential catalysts include the pending acquisition of GDS, possible high profile strategic agreements, CMS and CIH contracts, and agreements to commercialize MOON. Investment risks include disruption in the alternate site market from HCFA reimbursement changes, working capital management, and execution of the VHR strategy. Price Target $30